vs
GRAIL, Inc.（GRAL）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
GRAIL, Inc.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.2倍（$43.6M vs $35.5M），GRAIL, Inc.净利率更高（-227.5% vs -304.2%，领先76.8%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 14.0%），RECURSION PHARMACEUTICALS, INC.自由现金流更多（$-47.3M vs $-63.9M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 27.7%）
GRAIL是2015年成立的美国生物技术企业，总部位于加利福尼亚州门洛帕克，核心业务是研发面向无症状人群的癌症早期筛查检测产品。该公司最初是基因测序企业Illumina旗下的初创子公司，2021年被Illumina全资收购。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
GRAL vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $43.6M | $35.5M |
| 净利润 | $-99.2M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | -285.4% | -304.8% |
| 净利率 | -227.5% | -304.2% |
| 营收同比 | 14.0% | 681.7% |
| 净利润同比 | -2.2% | 39.6% |
| 每股收益（稀释后） | $-2.37 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $43.6M | $35.5M | ||
| Q3 25 | $36.2M | $5.2M | ||
| Q2 25 | $35.5M | $19.2M | ||
| Q1 25 | $31.8M | $14.7M | ||
| Q4 24 | $38.3M | $4.5M | ||
| Q3 24 | $28.7M | $26.1M | ||
| Q2 24 | $32.0M | $14.4M | ||
| Q1 24 | $26.7M | $13.8M |
| Q4 25 | $-99.2M | $-108.1M | ||
| Q3 25 | $-89.0M | $-162.3M | ||
| Q2 25 | $-114.0M | $-171.9M | ||
| Q1 25 | $-106.2M | $-202.5M | ||
| Q4 24 | $-97.1M | $-178.9M | ||
| Q3 24 | $-125.7M | $-95.8M | ||
| Q2 24 | $-1.6B | $-97.5M | ||
| Q1 24 | $-218.9M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | -285.4% | -304.8% | ||
| Q3 25 | -346.2% | -3327.6% | ||
| Q2 25 | -446.9% | -916.8% | ||
| Q1 25 | -482.5% | -1297.9% | ||
| Q4 24 | -358.0% | -4042.4% | ||
| Q3 24 | -640.5% | -377.1% | ||
| Q2 24 | -5133.8% | -697.4% | ||
| Q1 24 | -851.1% | -698.4% |
| Q4 25 | -227.5% | -304.2% | ||
| Q3 25 | -245.8% | -3135.3% | ||
| Q2 25 | -320.7% | -894.2% | ||
| Q1 25 | -333.6% | -1373.3% | ||
| Q4 24 | -253.8% | -3935.5% | ||
| Q3 24 | -438.7% | -367.5% | ||
| Q2 24 | -4958.8% | -676.6% | ||
| Q1 24 | -819.3% | -662.4% |
| Q4 25 | $-2.37 | $-0.17 | ||
| Q3 25 | $-2.46 | $-0.36 | ||
| Q2 25 | $-3.18 | $-0.41 | ||
| Q1 25 | $-3.10 | $-0.50 | ||
| Q4 24 | $-1.49 | $-0.56 | ||
| Q3 24 | $-3.94 | $-0.34 | ||
| Q2 24 | $-51.06 | $-0.40 | ||
| Q1 24 | $-7.05 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $249.7M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $2.6B | $1.1B |
| 总资产 | $2.9B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $249.7M | $743.3M | ||
| Q3 25 | $126.9M | $659.8M | ||
| Q2 25 | $127.4M | $525.1M | ||
| Q1 25 | $133.9M | $500.5M | ||
| Q4 24 | $214.2M | $594.4M | ||
| Q3 24 | $853.6M | $427.6M | ||
| Q2 24 | $958.8M | $474.3M | ||
| Q1 24 | $199.7M | $296.3M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | $2.6B | $1.1B | ||
| Q3 25 | $2.2B | $1.0B | ||
| Q2 25 | $2.3B | $919.1M | ||
| Q1 25 | $2.4B | $933.9M | ||
| Q4 24 | $2.5B | $1.0B | ||
| Q3 24 | $2.6B | $524.6M | ||
| Q2 24 | $2.7B | $584.4M | ||
| Q1 24 | — | $401.2M |
| Q4 25 | $2.9B | $1.5B | ||
| Q3 25 | $2.6B | $1.4B | ||
| Q2 25 | $2.7B | $1.3B | ||
| Q1 25 | $2.8B | $1.3B | ||
| Q4 24 | $3.0B | $1.4B | ||
| Q3 24 | $3.1B | $726.5M | ||
| Q2 24 | $3.3B | $775.9M | ||
| Q1 24 | — | $557.8M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-63.8M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $-63.9M | $-47.3M |
| 自由现金流率自由现金流/营收 | -146.5% | -133.1% |
| 资本支出强度资本支出/营收 | 0.2% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-299.9M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $-63.8M | $-46.1M | ||
| Q3 25 | $-63.2M | $-117.4M | ||
| Q2 25 | $-77.0M | $-76.4M | ||
| Q1 25 | $-95.0M | $-132.0M | ||
| Q4 24 | — | $-115.4M | ||
| Q3 24 | $-104.6M | $-59.2M | ||
| Q2 24 | $-171.8M | $-82.2M | ||
| Q1 24 | $-207.3M | $-102.3M |
| Q4 25 | $-63.9M | $-47.3M | ||
| Q3 25 | $-63.6M | $-117.6M | ||
| Q2 25 | $-77.3M | $-79.6M | ||
| Q1 25 | $-95.1M | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | $-105.6M | $-63.8M | ||
| Q2 24 | $-173.2M | $-83.4M | ||
| Q1 24 | $-209.8M | $-109.0M |
| Q4 25 | -146.5% | -133.1% | ||
| Q3 25 | -175.8% | -2272.5% | ||
| Q2 25 | -217.6% | -413.9% | ||
| Q1 25 | -298.6% | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | -368.4% | -244.6% | ||
| Q2 24 | -541.7% | -578.5% | ||
| Q1 24 | -785.3% | -789.9% |
| Q4 25 | 0.2% | 3.5% | ||
| Q3 25 | 1.1% | 4.7% | ||
| Q2 25 | 1.0% | 16.4% | ||
| Q1 25 | 0.2% | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | 3.4% | 17.5% | ||
| Q2 24 | 4.3% | 8.2% | ||
| Q1 24 | 9.5% | 48.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GRAL
| Screening Revenue | $42.3M | 97% |
| Developmental Services Revenue | $1.3M | 3% |
RXRX
暂无分部数据
